US 11,793,773 B2
Methods and compositions for preventing or treating calciphylaxis
James A. Tumlin, Lawrenceville, GA (US); Paul L. Darke, Hingham, MA (US); and John M. Rudey, New York, NY (US)
Assigned to Epizon Pharma, Inc., New York, NY (US)
Filed by Epizon Pharma, Inc., New York, NY (US)
Filed on Jun. 16, 2021, as Appl. No. 17/349,663.
Application 16/902,705 is a division of application No. 16/435,230, filed on Jun. 7, 2019, granted, now 10,736,858, issued on Aug. 11, 2020.
Application 17/349,663 is a continuation of application No. 16/902,705, filed on Jun. 16, 2020, granted, now 11,065,212.
Claims priority of provisional application 62/682,794, filed on Jun. 8, 2018.
Prior Publication US 2021/0378987 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/122 (2006.01); A61K 31/047 (2006.01); A61P 13/12 (2006.01); A61P 3/14 (2006.01); A61K 31/405 (2006.01); A61K 31/40 (2006.01); A61K 31/47 (2006.01); A61K 31/22 (2006.01); A61K 31/505 (2006.01); A61K 31/366 (2006.01)
CPC A61K 31/122 (2013.01) [A61K 31/047 (2013.01); A61K 31/22 (2013.01); A61K 31/366 (2013.01); A61K 31/40 (2013.01); A61K 31/405 (2013.01); A61K 31/47 (2013.01); A61K 31/505 (2013.01); A61P 3/14 (2018.01); A61P 13/12 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating calciphylaxis in a human subject in need thereof, the method comprising administering to the human subject a composition comprising menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) thereby to treat calciphylaxis in the subject, whereupon the administration of the MK-7 and/or MKH2-7 increases a plasma level of Fetuin A relative to the plasma level of Fetuin A prior to administration.